Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro

Cancer Immunology, Immunotherapy

Volumn 55, Issue 4, 2006, Pages 375-385

  Ren, Su Ping ^a   Wu, Chu Tse ^a   Huang, Wen Rong ^a   Lu, Zhuo Zhuang ^a   Jia, Xiang Xu ^a   Wang, Lan ^a   Lao, Miao Fen ^a   Wang, Li Sheng ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Adenoviral vector; B7 1 costimulatory molecule; Granulocyte macrophage colony stimulating factor; Immunotherapy; Multiple myeloma; p53 tumor suppressor gene

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; EVALUATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGENICITY; MULTIPLE MYELOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; VACCINATION; WILD TYPE;

ADENOVIRIDAE; ANTIGENS, CD80; APOPTOSIS; BLOTTING, WESTERN; CANCER VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENES, P53; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; MULTIPLE MYELOMA; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 30444444694     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0011-z     Document Type: Article

References (28)

1. Gregory W, Richards M, Malpas J (1992) Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10:336
2. Kyle RA (2000) The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy. Ann Oncol 11:55
3. Chiusolo P, Sica S, Piccirillo N, Giordano G, Laurenti L, La Barbera EO, De Stefano V, Serafini R, Leone G (2001) Molecular and clinical following-up after stem cell transplantation for multiple myeloma. Ann Hematol 80:90
4. Gahrton G, Björkstrand B (2000) Progress in haematopoietic stem cell transplantation for multiple myeloma. J Intern Med 248:185
5. Tarte K, Zhang XG, Legouffe E, Hertog C, Mehtali M, Rossi JF, Klein B (1999) Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. J Immunol 163:514
6. Brown RD, Pope B, Gibson J, Murray A, Sze D, Hart D, Joshua D (2000) Dendritic cells from patients with myeloma are numerically normal but functionally defective due to TGFβ and IL-10 inhibition of the upregulation of CD80 expression after huCD40L stimulation. Blood 96:161a
7. Gorschluter M, Ziske C, Glasmacher A, Schmidt-Wolf IG (2001) Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma. Clin Canc Res 7:2195
8. Hayashi T, Hideshima T, Akiyama M, Raje N, Richardson P, Chauhan D, Anderson KC (2003) Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 102:1435
9. Pan PY, Li Y, Li Q, Gu P, Martinet O, Thung S, Chen SH (2004) In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery. Cancer Immunol Immunother 53:17
10. Mellman I, Steinman RM (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255
11. Qiu ZH, Lao MF, Wu ZZ (2001) Construction of recombinant Adenovirus co-expressing human wild-type p53, GM-CSF and B7-1 genes (in Chinese). Chin J Biochem Mol Biol 17:329
12. Fiserova A, Hajek R, Holubova V, Buchler T, Sobotka J, Kovarova R, Musilova R, Bourkova L, Bulikova A, Mareschova I, Janackova Z, Vanova P, Kuglik P, Vorlicek J, Penka M (2002) Detection of 13q abnormalities in multiple myeloma using immunomagnetically selected plasma cells. Neoplasma 49:300
13. Boyum A (1964) Separation of white blood cells. Nature 204:793
14. Tu Y, Xu FH, Liu J, Vescio R, Berenson J, FAdy C, Lichtenstein A (1996) Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 88:1805
15. Sun RX, Lu ZY, Wijdenes J, Brochier J, Hertog C, Rossi JF, Klein B (1997) Large scale and clinical grade purification of syndecan-1 + malignant plasma cells. J Immunol Methods 205:73
16. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS (2001) Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 14:1052
17. Wang KS, Frank DA, Ritz J (2000) Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood 95:3183
18. Turner JG, Tan J, Crucian BE, Sullivan DM, Ballester OF, Dalton WS, Yang NS, Burkholder JK, Yu H (1998) Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. Hum Gene Ther 91:1121
19. Li ZH, Wen XY, Mandelbaum S, Falcioni N, Hawley TS, Hawley RG, Stewart AK(2003) Improved therapeutic outcome following combination immunogene vaccination therapy in murine myeloma. Leuk Lymphoma 44:1775
20. Wendtner CM, Nolle A, Mangold E, Buhmann R, Maass G, Chiorini JA, Winnacker EL, Emmerich B, Kotin RM, Hallek M (1997) Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Ther 4:726
21. Dotti G, Savoldo B, Takahashi S, Goltsova T, Brown M, Rill D, Rooney C, Brenner M (2001) Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. Exp Hematol 29:95
22. Dotti G, Savoldo B, Yotnda P, Rill D, Brenner MK (2002) Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells. Blood 100:200
23. Liu Q, Gazitt Y (2000) Adenovirus-mediated delivery of p53 results in substantial apoptosis to myeloma cells and is not cytotoxic to flow-sorted CD34+ hematopoetic progenitor cells and normal lymphocytes. Exp Hematol 28:1354
24. Ruffini PA, Biragyn A, Kwak LW (2002) Recent advances in multiple myeloma immunotherapy. Biomed Pharmacother 56:129
25. Trudel S, Li Z, Dodgson C, Nanji S, Wan Y, Voralia M, Hitt M, Gauldie J, Graham FL, Stewart AK (2001) Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - a phase I study. Leukemia 15:846
26. Qiu ZH, Wu ZZ, Lao MF, Pan LZ, Li YM (2002) Growth suppression and immunogenicity enhancement of Hep-2 or primary laryngeal cancer cells by adenovirus-mediated cotransfer of human wild-type p53, granulocyte-macrophage colony-stimulating factor and B7-1 genes. Cancer Lett 182:147
27. Qiu ZH, Lao MF, Wang YF, Wu ZZ (1999) The expression of multi-genes via a recombinant Adenovirus and their effects of inducing apoptosis on lung cancer cells (in Chinese). Chin J Cancer Biother 6:83
28. Shi M, Wang FS, Liu MX, Zhang B, Lei ZY, Qiu ZH, Gao LX, Wu ZZ (2001) Enhanced chemosensitivity to anticancer agents in hepatocellular carcinoma cell lines transduced with recombinant adenoviral vector expressing wild-type human p53 genes in vitro (in Chinese). Chin J Cancer Biother 8:80